Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study of the Safety and Efficacy of Anti-CD70-CAR-T Cell Injection in Patients With Locally Advanced or Relapsed/Metastatic Renal Cell Carcinoma With CD70+ Inoperable

NCT06586658 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.

NCT NCT06586658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06586658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study of the Safety and Efficacy of Anti-CD70-CAR-T Cell Injection in Patients With Locally Advanced or Relapsed/Metastatic Renal Cell Carcinoma With CD70+ Inoperable
Lead sponsor
Shanghai Changzheng Hospital
Phase
Phase 1
Overall status
Suspended
Start date
September 6, 2024
Completion date
July 16, 2027
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma